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Introduction
Th   e in-hospital mortality for acute myocardial infarction 
(AMI) is currently around 7% [1]. Death is related 
predominantly to the development of cardiogenic shock, 
which aﬀ  ects 5% to 10% of all cases of AMI and has a 
mortality rate of 50% to 90% [2,3]. Patients who develop 
cardiogenic shock frequently require critical care 
services, and AMI is one of the 10 leading causes for 
admission to adult critical care units [4]. Over the past 
three decades, revascularization therapy has revolution-
ized care for these patients. Recent studies support 
prompt percutaneous coronary intervention (PCI) when 
there is electrocardiographic evidence of an AMI [5], and 
if PCI is not available within 90 minutes, ﬁ  brinolysis 
should be delivered within 30 minutes [6,7].
Despite these developments, there has been little 
progress in reducing mortality from cardiogenic shock 
complicating an AMI [8]. Part of the reason for this is 
that impaired cardiac contractility may persist many 
hours after revascularization, an observation described 
as myocardial stunning [9]. Interventions that can assist 
or completely supplant the patient’s own cardiac output 
may support these patients until the stunned myo-
cardium recovers (bridge to recovery). Recovery can be 
predicted using peak serum creatinine kinase levels [10] 
or contrast echocardiography [11], but even when 
recovery does not occur, mechanical circulatory support 
may provide time to determine whether longer-term 
therapies are appropriate (bridge to decision). In this 
review, we will outline the various techniques of 
mechanical circulatory support and discuss the evidence 
for their use in cardiogenic shock complicating AMI.
Initial management
Eﬀ   ective treatment of cardiogenic shock begins with 
early recognition, prompt pharmacological intervention, 
and appropriate respiratory support. Cardiogenic shock 
is deﬁ  ned by evidence of tissue hypoperfusion, such as 
cool peripheries, oliguria, and elevated lactate, in the 
setting of cardiac dysfunction and adequate ﬁ  lling 
pressures (Table  1). Hemodynamic criteria include a 
systolic blood pressure of less than 90 mm Hg for more 
than 30 minutes, a cardiac index of less than 2.2 L/min 
per m2, and a pulmonary artery occlusion pressure of 
greater than 15  mm  Hg [12]. An in-depth review of 
pharmacological and respiratory support for cardiogenic 
shock is beyond the scope of this article and can be found 
elsewhere [13]. However, pharmacological interventions 
predominately involve inotropic support that may 
perpetuate ischaemia by increasing myocardial oxygen 
demand. Th   erefore, mechanical circulatory support 
should be considered early when inotropes have been 
initiated.
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Intra-aortic balloon pumps (IABPs) are the most 
commonly used form of mechanical circulatory support 
[14]. Th  ey were ﬁ  rst used in humans in 1968 [15], and 
percutaneous devices were introduced in 1980 [16]. Th  e 
device consists of a balloon catheter and a pump console 
that inﬂ   ates the balloon with helium. Th  e balloon 
catheter is placed in the aorta, with the tip just distal to 
the origin of the left subclavian artery (Figure  1). Th  e 
balloon is inﬂ  ated during diastole, displacing aortic blood 
and augmenting diastolic pressure. Prior to systole, the 
balloon is deﬂ  ated, reducing afterload and facilitating left 
ventricular emptying. In cardiogenic shock, these hemo-
dynamic eﬀ   ects result in reduced myocardial oxygen 
demand, enhanced coronary blood ﬂ  ow, and increased 
cardiac output.
Inﬂ   ation timing is determined using either the 
electrocardiogram or the arterial pressure waveform. In 
the latest devices, inﬂ  ation timing can be controlled with 
a physiologic timing algorithm that predicts aortic valve 
closure. When combined with R wave or pressure predic-
tive deﬂ  ation, this method maintains balloon synchrony 
even in patients with severe tachyarrhythmias [17].
As well as providing improved synchrony, modern 
IABPs have reduced vascular complications. Data from 
the Benchmark registry, which has collected outcomes 
for over 37,000 patient episodes [18], demonstrate that 
smaller (8 to 9.5 French) catheter sheaths have reduced 
the total complication rate to 2.6% and cut major 
complications, including limb, bowel, and renal ischemia, 
to under 0.5%. As a result, mortality directly attributable 
to IABP use is currently less than 0.05% [19]. Owing to a 
higher risk of limb ischemia, these devices, even with 
smaller catheters, should be used cautiously in patients 
with severe peripheral vascular disease. IABPs are not 
suitable for all patients and are speciﬁ  cally  contra-
indicated in those with severe aortic regurgitation, aortic 
dissection, or large aneurysms.
Clinical evidence supporting intra-aortic balloon 
pump in cardiogenic shock
Attempts to study IABP use in cardiogenic shock have 
been aﬀ  ected by poor recruitment. Th   is may reﬂ  ect the 
diﬃ   culty of obtaining timely consent and randomization 
in the critically ill. For example, the SMASH (Swiss 
Multicenter Evaluation of Early Angioplasty for Shock 
Following Myocardial Infarction) study was stopped after 
recruiting only 55 patients during a 4-year period [20]. 
Similarly, the TACTICS (Th  rombolysis and Counter-
pulsation to Improve Survival in Myocardial Infarction 
Complicated by Hypotension and Suspected Cardiogenic 
Shock) trial was stopped after 3 years when only 57 out of 
a planned 538 patients were randomly assigned [21].
Early experiences using IABPs in the treatment of 
cardiogenic shock secondary to AMI were disappointing. 
Two studies published prior to the availability of 
reperfusion therapy reported no beneﬁ  t (Table 2) [22,23]. 
Th   is is not surprising since patients who develop 
Table 1. Cardiogenic shock criteria
Hemodynamic criteria
  Systolic blood pressure (SBP) of less than 90 mm Hg for greater than 
 30  minutes
  SBP drop of greater than 30 mm Hg below basal for greater than 
  30 minutes in patients with hypertension
  Use of vasopressors and inotropes to keep SBP greater than 90 mm Hg
  Cardiac index of less than 2.2 L/min per m2
  Pulmonary artery occlusion pressure of greater than 15 mm Hg
Signs of tissue hypoperfusion
  Pale, cool, and clammy peripheries
  Prolonged capillary refi  ll times
  Altered mental status/confusion
 Oliguria
 Pulmonary  congestion
 Tachycardia
 Elevated  lactate
  Mixed venous saturation of less than 65%
Figure 1. Pictorial representation of intra-aortic balloon pump 
within the aorta, showing placement just distal to subclavian 
artery. Reprinted with permission from Maquet GmbH & Co. KG 
(Rastatt, Germany).
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40% of their left ventricle [24]. It is therefore unlikely that 
IABP support would be successful without deﬁ  nitive 
reperfusion therapy.
In 1997, Kovack and colleagues [25] demonstrated that 
patients who developed cardiogenic shock complicating 
an AMI were twice as likely to survive when an IABP was 
used in conjunction with pharmocological reperfusion 
strategies (Table 2). In the same year, the GUSTO-I 
(Global Utilization of Streptokinase and Tissue Plasmino-
gen Activator for Occluded Coronary Arteries) trial 
reported that early IABP use was associated with a trend 
toward lower 30-day (47% versus 60%; P = 0.06) and 
1-year (57% versus 67%; P = 0.04) mortality rates in 
patients who presented with cardiogenic shock compli-
cat  ing an AMI [26]. Analysis of the larger SHOCK 
(Should We Emergently Revascularize Occluded Coro-
nary Arteries for Cardiogenic Shock) trial (1,190 patients) 
conﬁ  rmed this beneﬁ  t, demonstrating statistically signi  ﬁ  -
cant lower in-hospital mortality for cardiogenic shock 
patients who received IABP verses those who did not 
(50% versus 72%; P ≤0.0001) [27]. However, a signi  ﬁ    cant 
confounding factor in these studies was a higher number 
of revascularization procedures in the IABP group.
To eliminate confounding, the SHOCK data were re-
evaluated comparing IABP plus ﬁ  brinolysis  with 
ﬁ  brinolysis alone. In this analysis, in-hospital mortality 
was still improved by 25% (47% versus 63%; P = 0.007) 
[27]. A similar beneﬁ  t was observed in the larger National 
Registry of Myocardial Infarction 2 (NRMI-2) (n = 23,180 
patients), in which the use of IABP as an adjunct to 
ﬁ   brinolysis, in cardiogenic shock, reduced in-hospital 
odds of death by 18% (odds ratio (OR) 0.82, 95% 
conﬁ   dence interval (CI) 0.72 to 0.93) [28]. A recent 
meta-analysis by Sjauw and colleagues [29] demonstrated 
that this beneﬁ  t remains statistically signiﬁ  cant beyond 
the in-hospital period, with an absolute decrease in 
30-day mortality of 18% (95% CI 16% to 20%; P <0.0001).
IABP beneﬁ   ts are less clear for cardiogenic shock 
patients who undergo primary PCI. In the SHOCK trial, 
revascularization with PCI resulted in a signiﬁ  cant 
reduction of mortality when compared with medical 
therapy, including ﬁ  brinolysis. Importantly, IABP use was 
86% in both groups, and mortality in the medical therapy 
group was lower than expected [8]. Th  is suggests that 
IABP plus medical therapy may result in lower mortality 
and that IABP plus PCI further improves mortality. In 
contrast, the NRMI-2 study observed that IABP as an 
adjunct to primary PCI resulted in a higher mortality 
(OR 1.27, 95% CI 1.07 to 1.50) in patients with 
cardiogenic shock complicating an AMI [28]. Th  is 
negative association is also evident in the recent meta-
analysis by Sjauw and colleagues [29]. However, for this 
part of their analysis, only two registries were used: the 
NRMI-2 study and the data of Sjauw and colleagues. In 
the absence of randomization, the trend may be 
confounded since patients receiving both PCI and an 
IABP in the NRMI-2 study were more likely to have 
cardiogenic shock complicated by previous PCI (OR 1.85, 
CI 1.64 to 2.09) and experience an inter-hospital transfer 
(OR 2.57, CI 2.40 to 2.75) [28].
A more recent study that randomly assigned patients 
with AMI complicated by cardiogenic shock to either 
IABP plus PCI or PCI alone did not demonstrate 
signiﬁ  cant improvement in APACHE II (Acute Physio-
logy and Chronic Health Evaluation II) scores or 
mortality over the ﬁ  rst 4 days of admission (36.8% in the 
IABP group versus 28.6%) [30]. However, this study was 
Table 2. Mortality evidence supporting intra-aortic balloon pump use in cardiogenic shock complicating an acute 
myocardial infarction
Study Patients  IABPa No  IABPa  P value
Pre-thrombolysis     
  O’Rourke et al. [22] (1981)  30  50%  43%  0.09
  Flaherty et al. [23] (1985)  20  52%  53%  -
Thrombolysis  era     
  Kovack et al. [25] (1997)  335  93%  37%  0.0002
  GUSTO-I [26] (1997)  310  47%b  60%b  0.06
  SHOCK [27] (2000)  856  47%  63%  0.007
  NRMI-2 [28] (2001)  12,054c  49% 67%  -
Reperfusion by PCI       
  NRMI-2 [28] (2001)  7,881c  47% 42%  -
aIn-hospital mortality expressed as a percentage. bThirty-day mortality. cTotal number of patients in the study, including those with no reperfusion therapy, was 23,180. 
GUSTO-I, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries; IABP, intra-aortic balloon pump; NRMI-2, National 
Registry of Myocardial Infarction 2; PCI, percutaneous coronary intervention; SHOCK, Should We Emergently Revascularize Occluded Coronary Arteries for Cardiogenic 
Shock.
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clinical trials are required to resolve this issue and 
address whether the current American Heart Association 
and American College of Cardiology guidelines recom-
mend  ing PCI and IABP in the setting of cardiogenic 
shock complicating AMI require revision [31]. In the 
meantime, we recommend IABP use in any patient 
meeting the criteria for cardiogenic shock in the setting 
of an AMI when inotrope therapy has been initiated, 
whether the patient has received PCI or thrombolysis or 
neither. IABPs are more widely available than more 
complex forms of mechanical circulatory support, have a 
low complication rate, and decrease myocardial oxygen 
demand. IABPs should be routinely available at centers 
treating patients with AMI.
Extracorporeal membrane oxygenation
When there is evidence of inadequate tissue oxygen 
delivery despite IABP, invasive ventilation, and inotropes, 
full circulatory support should be considered. Extracor-
poreal membrane oxygenation (ECMO) can subsume the 
function of both heart and lungs and was ﬁ  rst successfully 
used in adults in 1972 [32]. De-oxygenated blood is 
removed from the body, pumped through an artiﬁ  cial 
oxygenator, and returned to the circulation. Modern 
oxygenators consist of multiple, small hollow ﬁ  bers lined 
with polymethylpentene and allow gas but not liquid 
transfer. Oxygen and carbon dioxide exchange is achieved 
as blood runs through the center of the ﬁ  bers and an 
oxygen/air mix ﬂ   ows on the outside. Blood ﬂ  ow  is 
generated by a centrifugal pump, where a rotating 
impeller spins blood outwards, creating centrifugal 
acceler  ation. Since no compression is involved, high ﬂ  ow 
rates can be generated with minimal trauma to blood 
components.
ECMO can be broadly categorized into two types: 
veno-venous ECMO (VV-ECMO) and veno-arterial 
ECMO (VA-ECMO) (Figure 2). Th   e type selected depends 
on therapeutic goals. VV-ECMO is appropriate only for 
respiratory failure. VA-ECMO is used for cardiogenic 
shock and is currently the fastest growing indication for 
ECMO worldwide [33]. In adults, blood is usually 
removed through a femoral vein and returned through a 
femoral artery (peripheral ECMO). Occasionally, other 
cannulation strategies, such as directly cannulating the 
right atrium and aorta (central ECMO), may be 
employed.
Peripheral ECMO is less invasive, is easier to place, and 
can be placed percutaneously by surgeons or intensivists. 
It can be initiated quickly, making it more appropriate in 
emergencies. However, the cardiac output of the failing 
heart competes with retrograde ECMO ﬂ  ow from the 
femoral aortic cannula, producing admixing in the 
thoracic aorta and an increase in left ventricular wall 
tension. If there is concomitant respiratory failure, this 
can result in the delivery of inadequately oxygenated 
blood to the coronary and cerebral circulations and 
hinder recovery [34]. Central ECMO is not associated 
with this problem but is slower to initiate and may have a 
higher complication rate with bleeding and infection. It is 
usually conﬁ  ned to the support of patients after surgical 
revascularization. Peripheral VA-ECMO is adequate for 
most forms of cardiogenic shock, but frequent echo-
cardiography is necessary to monitor for progressive 
ventricular dilatation. If this develops, the left atrium can 
be vented either by changing the ECMO circuit 
Figure 2. Diagrammatic representation of peripheral veno-venous (VV-ECMO) and peripheral veno-arterial (VA-ECMO) extracorporeal 
membrane oxygenation. Reprinted with permission from Maquet GmbH & Co. KG (Rastatt, Germany).
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septostomy [35-37].
VA-ECMO is associated with bleeding in 30% to 60% of 
cases [38,39], sometimes requiring massive transfusions. 
New pumps and improved circuit biocompatibility allow 
lower levels of anticoagulation to be used and should 
reduce the impact of this complication. Clotting abnor-
malities predispose to hemorrhagic stroke, which, combined 
with circuit embolic complications such as air bubbles or 
clots, results in an overall stroke rate of 3% to 12% 
[33,40,41]. Other complications include nosocomial 
infec  tion in 50% to 60% [40,41] and multi-organ dys  func-
tion in 33% [39], although the contribution of ECMO is 
not easy to separate from the complications of severe 
critical illness. Device and circuit complications appear 
to be declining [33].
Evidence supporting extracorporeal membrane 
oxygenation in cardiogenic shock complicating 
acute myocardial infarction
In 1992, the Cleveland Clinic reported their experience 
with adult ECMO in postcardiotomy patients, of whom 
25.3% survived to discharge (Table  3) [42]. Two years 
later, this improved to 30.4% [43]. In 1999, Pittsburgh’s 
Allegheny Hospital reported ECMO use in high-risk 
patients undergoing PCI, of whom 85% survived to 
hospital discharge [44]. In 2008, two studies from Europe 
(Formica and colleagues [39] and Combes and colleagues 
[38]) demonstrated survival to discharge rates of 28% to 
31% when ECMO was used for postcardiotomy cardio-
genic shock or cardiogenic shock complicating AMI 
(Table 3). Patients were selected for ECMO if they failed 
conventional treatment, including inotropes, ventilation, 
or IABP. PCI was frequently used in the AMI patients.
Th  e variable survival rates reﬂ  ect that fact these are 
small single-center studies. Th   e Extracorporeal Life Support 
Organization (ELSO) registry addresses this limitation by 
recording the experience of over 170 ECMO centers 
worldwide. ELSO has accumulated data on over 40,000 
ECMO cases, of whom approximately 3,000 are adults. In 
2009, ELSO reported a survival rate of 39% for adult 
cardiogenic shock [33].
Th   e timing of ECMO is controversial, given the absence 
of guidelines. We recommend considering this therapy in 
patients with ongoing tissue hypoperfusion despite 
escalating inotropes, appropriate ventilatory support, 
and initiation of IABP. Evidence of tissue hypoperfusion 
includes worsening organ dysfunction, rising lactate, or 
falling central venous oxygen saturation. Inotrope scores 
[45,46] approaching 40 to 50 also indicate that mecha-
nical circulatory support may be required (Figure 3). 
Additional considerations include the rate of decompen-
sation as well as local resources (for example, how quickly 
ECMO can be initiated or whether the patient has to be 
transferred). Delaying ECMO until the inotrope score is 
60 may be associated with poorer outcomes [46].
Candidates should be selected only if signiﬁ  cant organ 
recovery is expected and there is no contraindication to 
long-term mechanical support or transplant (Table 4). 
Up to 60% of survivors cannot be weaned and require a 
ventricular assist device (VAD) or transplantation [38,41]. 
ECMO may therefore provide a bridge to decision; it is 
less costly than VADs, can be initiated quickly, and oﬀ  ers 
biventricular and respiratory support, thereby stabilizing 
patients while their suitability for a VAD or transplant is 
evaluated [47]. Institutions that do not provide this 
therapy should consider referring patients to an 
experienced center once IABP support has been initiated. 
In these situations, expert retrieval teams from the 
specialist center should provide transport [48,49].
Ventricular assist devices
VADs were ﬁ  rst used successfully in humans in 1966 [50]. 
Th   ree types are used: left ventricular assist (LVAD), right 
ventricular assist, or biventriciular assist (BiVAD) device. 
LVAD is the one most commonly used in cardiogenic 
shock complicating an AMI. Blood is removed from a 
cannula in the left atrium, or apex of the left ventricle, 
and pumped into the ascending aorta. Depending on the 
pump, ﬂ  ow will be pulsatile or continuous. In pulsatile 
pumps, also known as ﬁ  rst-generation VADs, blood ﬁ  lls a 
compliant, collapsible chamber that is intermittently 
compressed. Continuous ﬂ   ow pumps use an internal 
rotating impeller and these newer devices are referred to 
as second-generation pumps. Th  ey may be centrifugal 
(see ‘Extracorporeal membrane oxygenation’ section 
above) or axial, where the impeller is cylindrical with 
helical blades, similar to an Archimedes’ screw. Th  e  latest 
devices, third-generation VADs, spin and levitate the 
impeller within an electromagnetic ﬁ  eld, reducing blood 
trauma and prolonging serviceable life [51]. A range of 
Table 3. Evidence supporting extracorporeal membrane 
oxygenation use in cardiogenic shock complicating an 
acute myocardial infarction
   Survival  Cardiogenic  shock
Study Patients  ratea etiology
Golding et al. [42] (1992)  91  25.3%  Post-CABGb
Muehrcke et al. [43] (1996)  23  30.4%  Post-CABGb
Magovern et al. [44] (1999)  27  85%  UA or CHF
Formica et al. [39] (2008)  18  27.8%  AMI/Post-CABG
Combes et al. [38] (2008)  16  31.3%  AMI
ELSO [33] (2009)  153c  39% Not  defi   ned
aSurvival to hospital discharge. bPostcardiotomy patients who were unable to 
wean off   bypass or developed postoperative cardiogenic shock. cNumber of 
extracorporeal membrane oxygenation runs. AMI, acute myocardial infarction; 
CABG, coronary artery bypass graft; CHF, congestive heart failure; ELSO, 
Extracorporeal Life Support Organization; UA, unstable angina.
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whether cannulation is achieved percutaneously or 
centrally via a surgical sternotomy (Table 5).
Percutaneous left ventricular assist device
In acute cardiogenic shock complicating an MI, 
percutaneous LVADs (pLVADs) hold the most promise. 
Th   ey can be initiated quickly and do not require a sterno-
tomy. Th   e two most studied devices are the TandemHeart 
(CardiacAssist, Inc., Pittsburgh, PA, USA) and Impella 
(Abiomed, Aachen, Germany).
Th   e TandemHeart removes blood from the left atrium 
by means of a catheter that is transeptally placed in the 
left atrium via a femoral vein and returns it to the 
circulation through a femoral artery by means of a centri-
fugal pump (Figure 4). Th  is device has been compared 
with an IABP (Table 6). In one study, 41 patients 
presenting with cardiogenic shock following an AMI 
were randomly assigned to receive an IABP or the 
TandemHeart prior to PCI. Th   e TandemHeart resulted in 
a larger improvement in the cardiac power index 
compared with IABP (0.37 versus 0.28, P = 0.004) but did 
not translate into improved 30-day mortality (IABP 45% 
versus VAD 43%, P = 0.86) [52]. In another study, 30 
patients presenting with cardiogenic shock were ran-
domly assigned, and 70% of them had cardiogenic shock 
secondary to an AMI. In that study, the TandemHeart 
also improved hemodynamics more than the IABP did 
(Δ cardiac output 1.2 L/min versus 0.6 L/min, P <0.05) 
[53]. Again, this did not confer a signiﬁ  cant  30-day 
survival advantage (53% survival for TandemHeart versus 
64% for IABP). However, in both of these studies, a larger 
number of hemorrhagic complications and ischemic 
limbs were seen in the TandemHeart groups.
Figure 3. Simplifi  ed fl  ow diagram of initiation of mechanical circulatory support. Patients requiring full mechanical circulatory support should 
be referred to experienced, high-volume centers. *See Table 4 for contraindications to mechanical circulatory support. †Inotrope score = doses of 
dopamine + dobutamine μg/kg per min + [(epinephrine + norepinephrine + isoproterenol μg/kg per min) × 100] + [milrinone μg/kg per min × 15]. 
AMI, acute myocardial infarction; APO, acute pulmonary edema; AR, aortic regurgitation; ECMO, extracorporeal membrane oxygenation; IABP, intra-
aortic balloon pump; IPPV, invasive positive pressure ventilation; LVAD, left ventricular assist device; MCS, mechanical circulatory support.
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studied under conditions similar to those of the 
TandemHeart. Impella uses an axial pump that is placed 
across the aortic valve via one of the femoral arteries 
(Figure 5). In 2008, the ISAR-SHOCK study (Impella 
LP2.5 versus IABP in Cardiogenic SHOCK) randomly 
assigned 25 patients with cardiogenic shock following an 
AMI to receive the Impella or an IABP. Investigators 
found that the cardiac index after 30 minutes of support 
was signiﬁ  cantly increased in patients with the Impella 
LP2.5 compared with patients with IABP (Impella: 
Δ  cardiac index = 0.49 ± 0.46 L/min per m2; IABP: 
Δ cardiac index = 0.11 ± 0.31 L/min per m2; P = 0.02) 
[54]. Th   e mortality rate was 43% for both groups, and of 
particular note, there was no diﬀ  erence in major bleeding 
or distal limb ischemia between the two groups.
When these three studies are combined in a meta-
analysis, it is still not possible to detect a mortality beneﬁ  t 
[55]. However, it is arguable that an overall number of 
100 patients is still too small. In addition to oﬀ  ering no 
clear survival beneﬁ   ts, pLVADs provide only left 
Table 4. Contraindications to full mechanical circulatory 
support
Prolonged cardiopulmonary resuscitation with inadequate perfusion
Advanced age
Advanced malignancy
Existing organ dysfunction
  Advanced chronic obstructive pulmonary disease
  Interstitial lung disease
 Liver  cirrhosis
  Previous stroke with signifi  cant disability
 Dementia
  End-stage renal failure (relative)
Contraindication to anticoagulation (relative)
Contraindication to transplant (relative)
Table 5. Classifi  cation of ventricular assist devices
Access Ventricular  support  Abbreviation  Examplesa
Percutaneous  Left  pLVAD  TandemHeart (CardiacAssist, Inc., Pittsburgh, PA, USA)
        Impella 2.5L (Abiomed, Aachen, Germany)
        Impella 5L (Abiomed)
Surgical    
  Extracorporeal  Right/Left/Biventricular  RVAD/LVAD/BiVAD  CentriMag (Levitronix LLC, Waltham, MA, USA)
        Bio-Medicus (Eden Prairie, MN, USA)
        DeltaStream (Medos Medizintechnik AG, Stolberg, Germany)
  Implantable  Left  LVAD  HeartMate II (Thoratec Corporation, Pleasanton, CA, USA)
        Jarvik 2000 (Jarvik Heart Inc., New York, NY) and Incor 
        (Berlin Heart AG, Berlin, Germany)
        HeartAssist 5 (MicroMed Cardiovascular, Inc., Houston, TX, USA) 
        and DuraHeart (Terumo Heart Inc., Ann Arbor, MI, USA)
aThis list is not exhaustive and includes only a few continuous fl  ow devices. BiVAD, biventricular assist device; LVAD, left ventricular assist device; pLVAD, percutaneous 
left ventricular assist device; RVAD, right ventricular assist device.
Figure 4. Diagram of the TandemHeart percutaneous left 
ventricular assist device in situ in an adult. Reprinted with 
permission from CardiacAssist, Inc. (Pittsburgh, PA, USA), the 
manufacturer of this device.
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cardiogenic shock due to right ventri  cular ischemia, and 
although successful cases of percu  taneous right ventri-
cular assist [56,57] and even biventri  cular assist [58] have 
been reported, they required substantial modiﬁ  cation of 
existing technology. Despite this, the improved hemo-
dynamics are impressive and percutaneous devices are 
set to become increasingly important in the management 
of acute cardiogenic shock [59,60], especially if larger 
studies demonstrate that these hemodynamic beneﬁ  ts 
translate into signiﬁ  cant survival beneﬁ  ts.
Surgically placed ventricular assist device 
(extracorporeal and implantable)
In the acute setting of cardiogenic shock complicating 
AMI, surgical VAD placement has proven to be 
challenging. Th  e additional trauma of surgery com-
pounds the multi-organ dysfunction and coagulopathy 
associated with extracorporeal circuits. However, third-
generation pumps have been successfully surgically 
placed in the acute setting by means of cannulas tunneled 
through the chest wall. In one study, the Centrimag 
(Levitronix LLC, Waltham, MA, USA) was used to 
provide temporary BiVAD for 12 patients presenting 
with refractory shock following AMI. Eight patients were 
successfully bridged to an implantable VAD, and two 
patients recovered allowing device explantation. Overall 
1-year survival was 62.5% [61].
Implantable VADs allow patients to be discharged 
home, providing a bridge to transplant, bridge to 
recovery, or destination therapy. Destination therapy is 
particularly attractive since transplant demand greatly 
exceeds donor availability. Studies in the last decade have 
demonstrated that implantable pulsatile LVADs are 
superior to medical therapy in end-stage heart failure 
patients who are ineligible for a transplant [62,63]. 
Recently, it was demonstrated that third-generation 
devices result in decreased mortality and greater relia-
bility when compared with pulsatile LVADs [64].
VADs are susceptible to complications similar to those 
experienced with ECMO. Neurological insults aﬀ  ect 4% to 
12% of patients, infection 20% to 30%, and bleeding 30% to 
40% [52,53,65]. Device malfunction rates are improv  ing; 
over a 2-year period, less than 10% of implantable third-
generation pumps require replacement [64].
Th  e decision to initiate VAD therapy should be made 
under the same circumstances as those described above 
for ECMO. Th  e precise modality chosen depends on 
institutional experience and patient factors. For isolated 
left ventricular failure, with minimal respiratory 
Table 6. Comparative data of studies into ventricular assist device use in cardiogenic shock complicating an acute 
myocardial infarction. 
  Δ Cardiac output, L/min  30-day survival, percentage
Study Patients  VAD  IABP  P value  VAD  IABP
TandemHeart (pLVAD)           
 Thiele  et al. [52] (2005)  41  1.0  0.3  0.007  57  55
 Burkhoff   et al. [53] (2006)  42  1.2  0.6  -  53  64
Impella (pLVAD)           
 Seyfarth  et al. [54] (2008)  25  0.5  0.1  0.18  54  54
Centrimag (eBiVAD)           
 John  et al. [61] (2007)  12  Titrated for cardiac index >2.2 L/min per m2 75  N/A
eBiVAD, extracorporeal biventricular assist device; IABP, intra-aortic balloon pump; N/A, not applicable; pLVAD, percutaneous left ventricular assist device; VAD, 
ventricular assist device.
Figure 5. Diagram demonstrating the Impella LP2.5 axial fl  ow left 
ventricular assist device sitting across the aortic valve. Reprinted with 
permission from Abiomed (Aachen, Germany), the manufacturer of 
this device.
Cove and MacLaren Critical Care 2010, 14:235 
http://ccforum.com/content/14/5/235
Page 8 of 11disturbance, a pLVAD may be suﬃ   cient. Where there is 
concomitant respiratory failure or high ventilatory 
settings or when biventricular support is desired through 
a percutaneous approach, ECMO is more appropriate 
(Figure 3). Occasionally, the two may be used together 
[66]. In patients between these extremes, the factors of 
institutional experience, likelihood of recovery, and 
whether surgical revascularization is required will dictate 
choice. Finally, pursuing this technology is not without 
controversy in terms of resource allocation and ethics 
[67]. Th   ese issues vary substantially depending on health-
care infrastructure, ﬁ  nancing sources, and donor (as well 
as blood product) availability.
Conclusions
When cardiogenic shock complicating AMI is refractory 
to medical therapy, the only options available for survival 
are mechanical support strategies. Mechanical support 
can be applied in a stepwise progression starting with 
IABP support, followed by either ECMO or an LVAD. In 
the acute setting, these devices may provide circulatory 
support until the beneﬁ   ts of revascularization are 
realized. In the event that weaning is not possible, these 
devices serve as a bridge to decision or transplant. In 
patients who are ineligible for transplant, implantable 
VADs hold the promise of viable destination therapy.
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